.png)
Sensars is a neuromodulation company developing SENSY, an implantable system designed to restore protective foot sensation in people with diabetic neuropathy. When nerve damage takes away feeling in the foot, pressure and injuries go unnoticed. Ulcers, infections and amputations can follow, and SENSY aims to break that chain.
SENSY pairs smart insoles, which capture pressure and movement under the foot, with an electrode implanted in the nerve that passes that information on, helping patients feel their feet again. The device holds FDA Breakthrough Device Designation, and Sensars is raising a $3.5M seed round to reach its pivotal study.
Diabetic neuropathy takes away protective feeling in the foot, so pressure and injuries go unfelt. Ulcers follow, and some end in amputation. That adds up to an estimated 2.1 million ulcers and 0.5 million amputations a year, and an $80 billion burden. Sensars is developing SENSY to restore that sensation and stop the problem where it starts.
Diabetic neuropathy takes away protective feeling in the foot, so pressure and injuries go unfelt. Ulcers follow, and some end in amputation. That adds up to an estimated 2.1 million ulcers and 0.5 million amputations a year, and an $80 billion burden. Sensars is developing SENSY to restore that sensation and stop the problem where it starts.
Diabetic neuropathy takes away protective feeling in the foot, so pressure and injuries go unfelt. Ulcers follow, and some end in amputation. That adds up to an estimated 2.1 million ulcers and 0.5 million amputations a year, and an $80 billion burden. Sensars is developing SENSY to restore that sensation and stop the problem where it starts.
“Suddenly I could feel something that I couldn’t feel for 9 years.” (First-in-human study participant)
The Team
Francesco M. Petrini, PhD
Chief Operating Officer
A neural engineer with more than a decade of research experience. Francesco leads Sensars’ mission to restore lost sensation. He has won multiple startup and innovation awards and grants, holds two patent applications, and was named one of MIT Technology Review’s 35 Innovators Under 35 in 2019.
Guy Siman, MBA
Chief Operating Officer
A medtech executive with more than 16 years of experience at international medical device and industrial companies. Guy has led product development for Class III medical devices and guided products through CE mark registrations and IDE submissions. He was technical lead on two financing rounds totaling over $30 million, and holds a BSc in Mechanical Engineering (cum laude), an MBA and four granted patents.
Dan Merrill, PhD
Chief Science Officer
A neural stimulation scientist who joined Sensars in 2019 after 11 years in industry. Dan was previously Chief Scientist at the Alfred Mann Foundation and Chief Clinical Scientist at Ripple. He holds electrical engineering degrees from Cornell and a PhD from Case Western Reserve, and is a Fellow of the American Institute for Medical and Biological Engineering.
Join the deal
Join the Healthcare Shares Community
stay connected to the people shaping the future of healthcare.
